CONCLUSION
The bio/pharmaceutical industry is emerging from the current global economic situation into 2012 with a positive outlook.
The industry is spending more, becoming more efficient, and, perhaps most importantly, expressing great optimism. With sales
growth of between 14 and 18% this year, we will likely continue to see additional spending in new technology, capital equipment,
and hiring.
Eric Langer is president of BioPlan Associates, tel. 301.921.5979, elanger@bioplanassociates.com
, and a periodic contributor to Outsourcing Outlook.
REFERENCES
1. BioPlan Associates, 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers
and Contract Manufacturing Organizations (Rockville, MD), April 2011.
2. BioPlan Associates, Top 1000 Global Biopharmaceutical Facilities Index,
http://www.top1000bio.com/index.asp, accessed June 20, 2011.
3. R.A Rader, Biopharmaceutical Products in the US and European Markets (database), BioPlan Associates,
http://www.bioplanassociates.com/publications/pub_bpuseu.htm, accessed Jan. 16, 2012.
4. R. Rader, FDA Biopharmaceutical Product Approvals and Trends, Biotechnology Information Institute,
http://www.biopharma.com/approvals_2011.html, accessed Jan. 16, 2012.
|
